SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Dahlqvist Ulla) "

Sökning: WFRF:(Dahlqvist Ulla)

  • Resultat 1-10 av 21
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  • Arlien-Soborg, Mai C., et al. (författare)
  • Acromegaly management in the Nordic countries: A Delphi consensus survey
  • 2024
  • Ingår i: Clinical Endocrinology. - : WILEY. - 0300-0664 .- 1365-2265.
  • Tidskriftsartikel (refereegranskat)abstract
    • ObjectiveAcromegaly is associated with increased morbidity and mortality if left untreated. The therapeutic options include surgery, medical treatment, and radiotherapy. Several guidelines and recommendations on treatment algorithms and follow-up exist. However, not all recommendations are strictly evidence-based. To evaluate consensus on the treatment and follow-up of patients with acromegaly in the Nordic countries.MethodsA Delphi process was used to map the landscape of acromegaly management in Denmark, Sweden, Norway, Finland, and Iceland. An expert panel developed 37 statements on the treatment and follow-up of patients with acromegaly. Dedicated endocrinologists (n = 47) from the Nordic countries were invited to rate their extent of agreement with the statements, using a Likert-type scale (1-7). Consensus was defined as >= 80% of panelists rating their agreement as >= 5 or <= 3 on the Likert-type scale.ResultsConsensus was reached in 41% (15/37) of the statements. Panelists agreed that pituitary surgery remains first line treatment. There was general agreement to recommend first-generation somatostatin analog (SSA) treatment after failed surgery and to consider repeat surgery. In addition, there was agreement to recommend combination therapy with first-generation SSA and pegvisomant as second- or third-line treatment. In more than 50% of the statements, consensus was not achieved. Considerable disagreement existed regarding pegvisomant monotherapy, and treatment with pasireotide and dopamine agonists.ConclusionThis consensus exploration study on the management of patients with acromegaly in the Nordic countries revealed a relatively large degree of disagreement among experts, which mirrors the complexity of the disease and the shortage of evidence-based data.
  •  
3.
  • Arlien-Soborg, Mai C., et al. (författare)
  • Acromegaly management in the Nordic countries: A Delphi consensus survey
  • 2024
  • Ingår i: CLINICAL ENDOCRINOLOGY. - : WILEY. - 0300-0664 .- 1365-2265.
  • Tidskriftsartikel (refereegranskat)abstract
    • ObjectiveAcromegaly is associated with increased morbidity and mortality if left untreated. The therapeutic options include surgery, medical treatment, and radiotherapy. Several guidelines and recommendations on treatment algorithms and follow-up exist. However, not all recommendations are strictly evidence-based. To evaluate consensus on the treatment and follow-up of patients with acromegaly in the Nordic countries.MethodsA Delphi process was used to map the landscape of acromegaly management in Denmark, Sweden, Norway, Finland, and Iceland. An expert panel developed 37 statements on the treatment and follow-up of patients with acromegaly. Dedicated endocrinologists (n = 47) from the Nordic countries were invited to rate their extent of agreement with the statements, using a Likert-type scale (1-7). Consensus was defined as >= 80% of panelists rating their agreement as >= 5 or <= 3 on the Likert-type scale.ResultsConsensus was reached in 41% (15/37) of the statements. Panelists agreed that pituitary surgery remains first line treatment. There was general agreement to recommend first-generation somatostatin analog (SSA) treatment after failed surgery and to consider repeat surgery. In addition, there was agreement to recommend combination therapy with first-generation SSA and pegvisomant as second- or third-line treatment. In more than 50% of the statements, consensus was not achieved. Considerable disagreement existed regarding pegvisomant monotherapy, and treatment with pasireotide and dopamine agonists.ConclusionThis consensus exploration study on the management of patients with acromegaly in the Nordic countries revealed a relatively large degree of disagreement among experts, which mirrors the complexity of the disease and the shortage of evidence-based data.
  •  
4.
  • Arlien-Søborg, Mai C., et al. (författare)
  • Acromegaly management in the nordic countries : a Delphi consensus survey
  • 2024
  • Ingår i: Clinical Endocrinology. - : John Wiley & Sons. - 0300-0664 .- 1365-2265.
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective: Acromegaly is associated with increased morbidity and mortality if left untreated. The therapeutic options include surgery, medical treatment, and radiotherapy. Several guidelines and recommendations on treatment algorithms and follow-up exist. However, not all recommendations are strictly evidence-based. To evaluate consensus on the treatment and follow-up of patients with acromegaly in the Nordic countries.Methods: A Delphi process was used to map the landscape of acromegaly management in Denmark, Sweden, Norway, Finland, and Iceland. An expert panel developed 37 statements on the treatment and follow-up of patients with acromegaly. Dedicated endocrinologists (n = 47) from the Nordic countries were invited to rate their extent of agreement with the statements, using a Likert-type scale (1−7). Consensus was defined as ≥80% of panelists rating their agreement as ≥5 or ≤3 on the Likert-type scale.Results: Consensus was reached in 41% (15/37) of the statements. Panelists agreed that pituitary surgery remains first line treatment. There was general agreement to recommend first-generation somatostatin analog (SSA) treatment after failed surgery and to consider repeat surgery. In addition, there was agreement to recommend combination therapy with first-generation SSA and pegvisomant as second- or third-line treatment. In more than 50% of the statements, consensus was not achieved. Considerable disagreement existed regarding pegvisomant monotherapy, and treatment with pasireotide and dopamine agonists.Conclusion: This consensus exploration study on the management of patients with acromegaly in the Nordic countries revealed a relatively large degree of disagreement among experts, which mirrors the complexity of the disease and the shortage of evidence-based data.
  •  
5.
  •  
6.
  • Dahlqvist-Edberg, Ulla, et al. (författare)
  • Purification of a Ca2+-activated protease from rat erythrocytes and its possible effect on pyruvate kinase in vivo
  • 1981
  • Ingår i: Biochimica et Biophysica Acta-Enzymology. - : Elsevier BV. - 0005-2744. ; 660:1, s. 96-101
  • Tidskriftsartikel (refereegranskat)abstract
    • A Ca2+-activated protease with [32P]phosphopyruvate kinase as substrate was purified to about 50% from rat erythrocytes. The purification involved chromatography on Sepharose/Sephadex gels, DEAE-cellulose and (NH4)2SO4 precipitation. The protease required 3.3 mM Ca2+ for full activity. When pyruvate kinase (ATP: pyruvate 2-O-phosphotransferase, EC 2.7.1.40) was purified from erythrocytes incubated with [32P]phosphate it contained 0.5 mol [32P]phosphate/mol enzyme subunit. When 3.3 mM Ca2+ were added at hemolysis this incorporation decreased. The possible importance of this Ca2+-activated protease for the regulation of pyruvate kinase in erythrocytes is discussed.
  •  
7.
  •  
8.
  • Dahlqvist-Edberg, Ulla, et al. (författare)
  • The demonstration in rat liver cell sap of protein kinase and phosphoprotein phosphatase active on fructose-bisphosphatase
  • 1982
  • Ingår i: Biochimica et Biophysica Acta - Protein Structure and Molecular Enzymology. - : Elsevier BV. - 0167-4838 .- 1879-2588. ; 706:2, s. 239-244
  • Tidskriftsartikel (refereegranskat)abstract
    • A protein kinase active on fructose-bisphosphatase (D-fructose-1,6-bisphosphate 1-phosphohydrolase, EC 3.1.3.11) was demonstrated in rat liver cell sap. The protein kinase activity was stimulated by cyclic AMP and coincided with the activity of cyclic AMP-dependent protein kinase type I. In addition, three different peaks of phosphoprotein phosphatase active on [32P] phosphofructose-bisphosphatase were found on chromatography of rat liver cell sap on a DEAE-cellulose column. These phosphatases needed divalent cations for full activity. 5'-AMP, a negative modulator of fructose-bisphosphatase, had no effect on the phosphorylation-de-phosphorylation reactions of the enzyme. ATP and Ca2+ did not influence the dephosphorylation reaction of fructose-bisphosphatase.
  •  
9.
  • Dahlqvist Jönsson, Patrik, 1974-, et al. (författare)
  • Service users' experiences of participation in decision making in mental health services
  • 2015
  • Ingår i: Journal of Psychiatric and Mental Health Nursing. - Chichester : Wiley-Blackwell. - 1351-0126 .- 1365-2850. ; 22:9, s. 688-697
  • Tidskriftsartikel (refereegranskat)abstract
    • Service user participation in decision making is considered an essential component of recovery-oriented mental health services. Despite the potential of shared decision making to impact service users knowledge and positively influence their experience of decisional conflict, there is a lack of qualitative research on how participation in decision making is promoted from the perspective of psychiatric service users. In order to develop concrete methods that facilitate shared decision making, there is a need for increased knowledge regarding the users' own perspective. The aim of this study was to explore users' experiences of participation in decisions in mental health services in Sweden, and the kinds of support that may promote participation. Constructivist Grounded Theory (CGT) was utilized to analyse group and individual interviews with 20 users with experience of serious mental illness. The core category that emerged in the analysis described a 'struggle to be perceived as a competent and equal person' while three related categories including being the underdog, being controlled and being omitted described the difficulties of participating in decisions. The data analysis resulted in a model that describes internal and external conditions that influence the promotion of participation in decision making. The findings offer new insights from a user perspective and these can be utilized to develop and investigate concrete methods in order to promote user's participation in decisions.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 21
Typ av publikation
tidskriftsartikel (16)
konferensbidrag (4)
doktorsavhandling (1)
Typ av innehåll
refereegranskat (20)
övrigt vetenskapligt/konstnärligt (1)
Författare/redaktör
Ek, Pia (9)
Rydberg, Annika (3)
Feldt-Rasmussen, Ull ... (3)
Ekbom, Anders (3)
Fernlund, Eva (3)
Wahren-Herlenius, Ma ... (3)
visa fler...
Matikainen, Niina (3)
Theander, Elke (3)
Winqvist, Ola (3)
Olsson, Tommy (3)
Berinder, Katarina (3)
Burman, Pia (3)
Dahlqvist, Per (3)
Ekman, Bertil (3)
Salomonsson, Stina (3)
Sonesson, Sven-Erik (3)
Stochholm, Kirstine (3)
Ambrosi, Aurelie (3)
Zeffer, Elisabeth (3)
Dzikaite, Vijole (3)
Bergman, Gunnar (3)
Skogh, Thomas (3)
Fored, Michael (3)
Gadler, Fredrik (3)
Jonzon, Anders (3)
Blomqvist, Paul (3)
Melander, Mats (3)
Petersson, Maria (3)
Sandlund, Mikael (3)
Dal, Jakob (3)
Heck, Ansgar (3)
Husted, Eigil (3)
Feltoft, Claus Larse ... (3)
Andreassen, Mikkel (3)
Klose, Marianne Chri ... (3)
Nielsen, Torben Leo (3)
Andersen, Marianne S ... (3)
Christensen, Louise ... (3)
Krogh, Jesper (3)
Jarlov, Anne (3)
Bollerslev, Jens (3)
Nermoen, Ingrid (3)
Oksnes, Marianne (3)
Hoybye, Charlotte (3)
Akerman, Anna-karin (3)
Wahlberg, Jeanette (3)
Engstrom, Britt Eden (3)
Ragnarsson, Oskar (3)
Sigurjonsdottir, Hel ... (3)
Fougner, Stine Lyngv ... (3)
visa färre...
Lärosäte
Uppsala universitet (11)
Umeå universitet (6)
Linköpings universitet (4)
Högskolan i Halmstad (3)
Göteborgs universitet (2)
Lunds universitet (2)
visa fler...
Karolinska Institutet (2)
Högskolan Dalarna (2)
visa färre...
Språk
Engelska (21)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (15)
Naturvetenskap (3)
Samhällsvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy